Cardiocore Sets Benchmark for Rapid Data Delivery in Thorough QT Trials

Cardiocore Lab, Inc., a premier provider of centralized cardiac safety monitoring and analysis, announced an unprecedented achievement in electrocardiograph (ECG) data management. The company delivered a clean Thorough QT (TQT) data set—more than 13,000 ECGs—only five days after the study’s final ECG was acquired. With this accomplishment, Cardiocore sets a new standard for cardiac core lab performance.

(PRWEB) February 10, 2006 -- Cardiocore Lab, Inc., a premier provider of centralized cardiac safety monitoring and analysis, announced an unprecedented achievement in electrocardiograph (ECG) data management. The company delivered a clean Thorough QT (TQT) data set—more than 13,000 ECGs—only five days after the study’s final ECG was acquired. With this accomplishment, Cardiocore sets a new standard for cardiac core lab performance.

“Sponsors should never have to wait months to receive their TQT data,” said Cardiocore CEO, Jennifer Cotteleer. “Lackluster data management is often a result of transactional relationships between core labs and sponsors. Cardiocore is able to deliver superior service by engaging our customers in truly collaborative partnerships.”

“I consider Cardiocore to be a partner, not just a vendor,” said the Associate Director of Clinical Pharmacology from the trial sponsor, a mid-tier, multinational pharmaceutical company. “Going into a clinical trial, it is a great relief to know I can count on clean, quick data delivery. Working with Cardiocore, we have established a pattern of success."

Per the often quoted analysis by the Tufts Center for the Study of Drug Development, the average cost per day of clinical development is nearly $1 million. By that standard, the net savings from Cardiocore’s data management and operational efficiencies are several times greater than the cost of the entire Thorough QT protocol.

Cardiocore’s Chief Medical Officer, Lawrence Satin, MD, FACC, explained, “Successful conduct of a TQT study is reliant on many interdependent factors such as protocol design, reader expertise, data management and customer care. There is room for innovation in each of these areas. In this particular study, Cardiocore augmented our recorders with barcode scanners that were synchronized to the Phase I center’s wrist band codes—a solution that ensured accurate data while easing the workload for the investigative site personnel.”

About Cardiocore

Cardiocore’s clinical operations organization has provided superior centralized cardiac testing services to the pharmaceutical industry for 13 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, statistical analysis and consulting services such as protocol design. These services are supported by the company’s CardioCorrect® system featuring the HolterGateway™ and the CardioPortal™. Headquartered in Bethesda, MD, Cardicore is experienced in the design and implementation of Thorough QT Trials as well as cardiac safety and efficacy testing in Phases I, II and III clinical trials.

###